Abstract: Disclosed herein are compounds comprising dicarba-closo-dodecaborane. The compounds can be, for example, estrogen receptor beta (ER?) agonists. In some examples, the compounds can be selective ER? agonists. Also provided herein are methods of treating, preventing, or ameliorating cancer in a subject, suppressing tumor growth in a subject, treating an inflammatory disease in a subject, treating a neurodegenerative disease in a subject, treating a psychotropic disorder in a subject, or a combination thereof, by administering to a subject a therapeutically effective amount of one or more of the compounds or compositions described herein, or a pharmaceutically acceptable salt thereof.

Abstract: Aspects of the disclosure provide a method including determining a measurement configuration for one or more piezoelectric devices in an electronic apparatus. The electronic apparatus includes an electronic device mounted on a substrate block using a bonding layer. The one or more piezoelectric devices including a first subset and a second subset are attached to one of the electronic device and the bonding layer. The method includes performing, based on the measurement configuration, a defect measurement on the electronic apparatus by causing the first subset to transmit and the second subset to receive one or more acoustic signals. The method includes determining whether at least one mechanical defect is located in at least one of (i) the bonding layer, (ii) the electronic device, (iii) the substrate block, (iv) interfaces of the electronic device, the bonding layer, and the substrate block based on the received one or more acoustic signals.

Abstract: Membranes, methods of making the membranes, and methods of using the membranes are described herein. The membranes can comprise a support layer, and a selective polymer layer disposed on the support layer. The selective polymer layer can comprise a selective polymer matrix and carbon nanotubes dispersed within the selective polymer matrix. The carbon nanotubes can comprise multi-walled carbon nanotubes wrapped in a hydrophilic polymer, such as polyvinylpyrrolidone or a copolymer thereof, such as poly(1-vinylpyrrolidone-co-vinyl acetate). The membranes can exhibit selective permeability to gases. As such, the membranes can be for the selective removal of carbon dioxide and/or hydrogen sulfide from hydrogen and/or nitrogen.

Abstract: Systems and methods include providing a gaseous alkane input stream and metal sulfide (MSx) particles that can react with an alkane in the gaseous alkane input stream to generate an alkene, a reduced metal sulfide (MSx?1) particle, and at least one of: hydrogen sulfide (H2S) and at least one sulfur containing compound selected from: S2, CS, and CS2. A product stream can be collected that includes the alkene and at least one of: hydrogen sulfide (H2S) and the at least one sulfur containing compound. A reduced metal sulfide (MSx?1) particle reacts with sulfur in a sulfur stream and can generate the metal sulfide (MSx) particle and hydrogen (H2).

Abstract: The present invention relates to a 3-((8-((1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethynyl)-N-phenylbenzamide derivative, a method for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating cancer. The derivative can significantly inhibit the proliferation of cancer cells by inhibiting kinases, particularly Bcr-Abl kinase or Bcr-Abl (T315I) kinase. Therefore, the derivative can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer.

Abstract: A system and method for joining dissimilar metals. In one embodiment, a method comprises providing a first metal plate, a second metal plate, and an intermediate body that is positioned between the first metal plate and the second metal plate. The first metal plate is then driven into the intermediate body, which causes at least a portion of the intermediate body to collide with the second metal plate. As a result, the material of the intermediate body joins the first metal plate to the second plate. In another embodiment, a method for joining dissimilar metals comprises providing a first metal that is not amenable to welding, a second metal that is joinable to the first metal, and an intermediate body that is not joinable to at least the first metal. The intermediate body may have at least one hole such that the first metal and the second metal are positioned over and on opposite sides of the hole(s). At least a portion of the second metal may then be driven into the hole(s) to be joined to first metal.

Abstract: A thermally stable polypeptide having FGF7 activity is provided. The polypeptide is a thermally stable polypeptide having FGF7 activity, wherein, in SEQ ID NO: 1, a 120th alanine (A) is substituted with cysteine (C), one including at least one substitution selected from substitution of a 126th lysine (K) with aspartic acid (D) and a 178th lysine (K) with glutamic acid (E) or aspartic acid (D) forms a salt bridge with a 175th arginine (R), and a 133rd cysteine (C) and a 137th cysteine (C) are disulfide bonded.

Abstract: A low inductance power module with low power loop inductance and high-power density is provided. The power module may include a vertical power loop structure, a cooling layer, and a thermal dissipation structure. The vertical power loop structure may utilize a substrate bottom conduction layer for electrical conduction. The thermal dissipation structure may be disposed between the substrate bottom conduction layer and the cooling layer. The vertical power loop structure may include integrated decoupling capacitors. Alternatively, the structure may include no integrated decoupling capacitors. The vertical power loop structure may include one or more half-bridge structures connected in parallel, each with its own integrated decoupling capacitors. The vertical power loop structure reduces power loop inductance in the power module, and the thermal dissipation structure provides electrical insulation, mechanical support, and thermal conduction.

Abstract: A method includes receiving a first polynomial and a second polynomial, both of order n?1 and forming d polynomial segments from both the first polynomial and the second polynomial such that each polynomial segment is of order (n/d)?1. The polynomial segments of the first polynomial and the d polynomial segments of the second polynomial are used to form segment products. Each segment product is divided into a first polynomial substructure of order n/d and a second polynomial substructure of order (n/d)?1. A first polynomial substructure containing the first n/d coefficients of a product of the first polynomial and the second polynomial is summed with a second polynomial substructure to form a sum substructure. The sum substructure is used multiple times to determine coefficients of a polynomial representing the modulo xn+1 of the product of the first polynomial and the second polynomial.

Abstract: The present invention relates to a nasal plug for diverting airflow from a natural flow path in a person's nostril. In some circumstances, the airflow is channeled and directed to a specific location in a person's nasal or sinus cavity. The person may adjust and self-select a preferred airflow path by adjusting the nasal plug's location in the nostril, e.g., rotating the plugs. A kit may include two plugs, which may be used singly or in combination with each other and are independently adjustable/rotatable. A method for reducing nasal discomfort or improving nasal functions by diverting channeled airflow in a nostril is also disclosed.

Abstract: The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-osmolar contrast agent, together with a rAAV9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone.

Abstract: Embodiments disclosed herein provide compositions, methods, and uses for recombinant vectors encoding Zika virus (ZIKV) protein subunits, and immunogenic compositions thereof. Certain embodiments provide recombinant vectors encoding ZIKV nonstructural protein 1 (NS 1), and optionally, ZIKV envelope (E) protein and premembrane (prM) protein. Other embodiments provide expression cassettes comprising a promoter operably linked to a polynucleotide that encodes the ZIKV NS 1 protein, and optionally ZIKV E and prM proteins. In some embodiments, the disclosed expression cassettes can be incorporated into a vector to produce a recombinant vector. Also provided are immunogenic compositions comprising one or more recombinant vectors described herein, and methods for inducing an immune response against ZIKV in a subject comprising administering to the subject an immunologically effective dose of an immunogenic composition of the present disclosure.

Abstract: The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-os-molar contrast agent, together with a rAA9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone.

Abstract: The exemplified systems and methods disclosed herein involve the contemporaneous and concurrent stimulation of both eyes of a patient with dissimilar visual scenes that substantially span an expected or normal visual field of both eyes. During an assessment via the exemplified system and methods, a test eye (i.e., eye being assessed) is presented a visual scene that is rich in contours (e.g., a scene with rich texture patterns) that substantially span an expected or normal visual field of a person while the non-tested eye is presented an impoverished visual scene (e.g., a contour-free or non-distinguishing-contour scene, e.g., with a homogeneous color, with respect to the contour-rich scene). Defects in the visual field can be detected by assessing for breaks or discontinuity in the observation of the contour-rich scene by the person.

Abstract: According to one aspect, the present disclosure provides a system for manufacturing transition structures including fiber threads embedded within a metal component. The system may include a supply of base sheet metal. The system may include a conveyor supported on a plurality of rollers and configured to move the base sheet metal in a production direction. The system may include a plurality of stages arranged in the production direction. Each stage may include a channel forming device configured to form a channel in the base sheet metal, a fiber inserting device configured to insert a portion of a fiber material into the channel, and one or more ultrasonic welders configured to consolidate a layer of metal foil over the fiber. The disclosure includes methods of using the system to produce transition structures and reinforced components.

Abstract: The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.

Abstract: Systems and methods are described herein for real-time data processing and for emergency planning. Scenario test data may be collected in real-time based on monitoring local or regional data to ascertain any anomaly phenomenon that may indicate an imminent danger or of concern. A computer-implemented method may include filtering a plurality of different test scenarios to identify a sub-set of test scenarios from the plurality of different test scenarios that may have similar behavior characteristics. A sub-set of test scenarios is provided to a trained neural network to identify one or more sub-set of test scenarios. The one or more identified sub-set of test scenarios may correspond to one or more anomaly test scenarios from the sub-set of test scenarios that is most likely to lead to an undesirable outcome. The neural network may be one of: a conventional neural network and a modular neural network.

Abstract: A system and method indicate capability for detecting methane leaks inside buildings. This approach provides the ability to detect methane behind high efficiency coated windows and can extract methane concentration (rather than concentration-path length product CL). Lock-in imaging technologies can facilitate lower laser transmitter power. A field deployable, hand held prototype sensor for use in remote sensing a appropriate standoff distances can support operational testing. Distance infrared imaging of methane is feasible. Fully characterized real time image of a methane cloud offers operational advantages in accuracy and safety as compared to current sensors.

Abstract: The present disclosure relates to systems and methods for characterizing a behavior change of a process. A behavior model that can include a set of behavior parameters can be generated based on behavior data characterizing a prior behavior change of a process. A stimulus parameter for a performance test can be determined based on the set of behavior parameters. An application of the performance test to the process can be controlled based on the stimulus parameter to provide a measure of behavior change of the process. Response data characterizing one or more responses associated with the process during the performance test can be received. The set of behavior parameters can be updated based on the response data to update the behavior model characterizing the behavior change of the process. In some examples, the behavior model can be evaluated to improve or affect a future behavior performance of the process.

Abstract: Disclosed are compounds that activate excitatory amino acid transporter 2 (EAAT2), as well as methods of using these compounds to treat or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.